### RETRACTION

# LncRNA NORAD Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer by Regulating miR-214/Akt/mTOR Axis [Retraction]

Tao W, Li Y, Zhu M, Li C, Li P. Onco Targets Ther. 2019;12:8841-8851.

We, the Editor and Publisher of the journal OncoTargets and Therapy have retracted the published article.

Following publication of the article, concerns were raised about the duplication of images from Figures 4 and 5 with images from an unrelated article. Specifically,

- The images for Figure 4D, BGC803 and BGC823, Ctrl, have been duplicated with images for Figure 4A, miR-519a mimics NC, 0Gy and Figure 4G, miR-519a mimics+OE-EphA2, 2Gy, respectively, from Gong S, Li Y, Lv L, et al. Restored microRNA-519a enhances the radiosensitivity of non-small cell lung cancer via suppressing EphA2. *Gene Ther.* 2022;29:588–600. https://doi.org/10.1038/s41434-020-00213-x.
- The image for Figure 5D, BGC803, pcNORAD+miR-214, has been duplicated with the image for Figure 4G, si-EphA2, 0Gy from Gong S, et al (2022).

The corresponding author did not respond to our queries and was unable to provide a satisfactory explanation for how the images came to be duplicated or provide satisfactory original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the Publisher and Editor requested to retract the article and the corresponding author was notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

## **OncoTargets and Therapy**

# **Dove**press

569

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.\$486070

Received: 8 July 2024 Accepted: 8 July 2024 Published: 10 July 2024

#### OncoTargets and Therapy 2024:17 569

© 2024 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).